{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:48:15Z","timestamp":1793659695701,"version":"4.5.1"},"reference-count":168,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","award":["RG-5-140-43"],"award-info":[{"award-number":["RG-5-140-43"]}],"id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Journal of Biological Sciences"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.sjbs.2023.103920","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T03:57:22Z","timestamp":1703908642000},"page":"103920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["An overview of multiple myeloma: A monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-3386","authenticated-orcid":false,"given":"Maisa Siddiq","family":"Abduh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.sjbs.2023.103920_b0005","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease MGUS and smoldering multiple myeloma","volume":"19","author":"Agarwal","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10753-021-01559-z","article-title":"Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance","volume":"45","author":"Al-Mansoori","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.sjbs.2023.103920_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699629","article-title":"Mcl-1 inhibition: managing malignancy in multiple myeloma","volume":"12","author":"Al-Odat","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.sjbs.2023.103920_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-019-0804-4","article-title":"Management of newly diagnosed elderly multiple myeloma patients","volume":"21","author":"Antoine-Pepeljugoski","year":"2019","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0035","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.sjbs.2023.103920_b0040","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/pr5005967","article-title":"Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry","volume":"13","author":"Barnidge","year":"2014","journal-title":"J. Proteome Res."},{"issue":"10297","key":"10.1016\/j.sjbs.2023.103920_b0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0050","first-page":"422","article-title":"Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back","volume":"64","author":"Bianchi","year":"2014","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","article-title":"Guidelines for the diagnosis and management of multiple myeloma 2011","volume":"154","author":"Bird","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.sjbs.2023.103920_b0060","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s40265-020-01433-6","article-title":"Venetoclax: a review in previously untreated chronic lymphocytic leukaemia","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.sjbs.2023.103920_b0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fonc.2020.00189","article-title":"Next-generation sequencing for clinical management of multiple myeloma: ready for prime time?","volume":"10","author":"Bolli","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0070","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0188-z","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia","volume":"4","author":"Boyiadzis","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17474086.2021.1909469","article-title":"A new decade: novel immunotherapies on the horizon for relapsed\/refractory multiple myeloma","volume":"14","author":"Braunstein","year":"2021","journal-title":"Expert Rev. Hematol."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0080","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.sjbs.2023.103920_b0085","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted therapy with immunoconjugates for multiple myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0090","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3109\/10428194.2015.1131278","article-title":"Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)","volume":"57","author":"Bruno","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.sjbs.2023.103920_b0095","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux","year":"2022","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.sjbs.2023.103920_b0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fonc.2018.00355","article-title":"Multiple myeloma exemplifies a model of cancer based on tissue disruption as the initiator event","volume":"8","author":"Capp","year":"2018","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.sjbs.2023.103920_b0105","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/cancers12082158","article-title":"Multiple myeloma as a bone disease? The tissue disruption-induced cell stochasticity (TiDiS) theory","volume":"12","author":"Capp","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.sjbs.2023.103920_b0110","doi-asserted-by":"crossref","first-page":"103640","DOI":"10.1016\/j.critrevonc.2022.103640","article-title":"A bone paradigm challenging the standard model of myeloma oncogenesis","volume":"172","author":"Capp","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.sjbs.2023.103920_b0115","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.3389\/fonc.2021.801851","article-title":"Minimal residual disease assessment in multiple myeloma patients: Minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.sjbs.2023.103920_b0120","first-page":"974","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.sjbs.2023.103920_b0125","doi-asserted-by":"crossref","first-page":"356","DOI":"10.12659\/PJR.901742","article-title":"Whole-body low-dose computed tomography (WBLDCT) in assessment of patients with multiple myeloma\u2013pilot study and standard imaging protocol suggestion","volume":"82","author":"Chrzan","year":"2017","journal-title":"Pol. J. Radiol."},{"issue":"978","key":"10.1016\/j.sjbs.2023.103920_b0130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/pgmj.2006.054627","article-title":"Management of paraproteinaemia","volume":"83","author":"Cook","year":"2007","journal-title":"Postgraduate Med. J."},{"key":"10.1016\/j.sjbs.2023.103920_b0135","doi-asserted-by":"crossref","unstructured":"Corradetti, V., Comai, G., Bini, C., La Manna, G., 2021. The Pathophysiology of Kidney Involvement in Multiple Myeloma and Monoclonal-Related Disorders. In: Management of Bone Disease and Kidney Failure in Multiple Myeloma: A Pocket Guide, pp. 159\u2013177.","DOI":"10.1007\/978-3-030-63662-3_9"},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0140","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin. Exp. Allergy"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0145","doi-asserted-by":"crossref","first-page":"e2017053","DOI":"10.4084\/mjhid.2017.053","article-title":"Non-secretory myeloma: ready for a new definition?","volume":"9","author":"Corso","year":"2017","journal-title":"Mediterranean J. Hematol. Infect. Dis."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.sjbs.2023.103920_b0155","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0160","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0165","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.sjbs.2023.103920_b0170","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0175","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"De Weers","year":"2011","journal-title":"J. Immunol."},{"issue":"s1","key":"10.1016\/j.sjbs.2023.103920_b0180","doi-asserted-by":"crossref","first-page":"8956","DOI":"10.4081\/hr.2020.8956","article-title":"How I manage frontline transplant-ineligible multiple myeloma","volume":"12","author":"Derudas","year":"2020","journal-title":"Hematol. Rep."},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0185","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cancers13040863","article-title":"Role of stem cell transplantation in multiple myeloma","volume":"13","author":"Devarakonda","year":"2021","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.sjbs.2023.103920_b0190","first-page":"4701","article-title":"Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"8","key":"10.1016\/j.sjbs.2023.103920_b0195","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0200","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0205","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"9727","key":"10.1016\/j.sjbs.2023.103920_b0210","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992\u20132004","volume":"144","author":"Dores","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"10068","key":"10.1016\/j.sjbs.2023.103920_b0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.sjbs.2023.103920_b0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0230","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","article-title":"Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability","volume":"33","author":"Dutta","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.sjbs.2023.103920_b0240","first-page":"684","article-title":"Multiple myeloma: from diagnosis to treatment","volume":"42","author":"Eslick","year":"2013","journal-title":"Aust. Family Phys."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0250","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/CCO.0b013e3283592331","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"24","author":"Falanga","year":"2012","journal-title":"Curr. Opin. Oncol."},{"issue":"10","key":"10.1016\/j.sjbs.2023.103920_b0255","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/cancers13102326","article-title":"The role of AP-1 transcription factors in plasma cell biology and multiple myeloma pathophysiology","volume":"13","author":"Fan","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7861\/clinmedicine.19-1-58","article-title":"Haematology: multiple myeloma","volume":"19","author":"Firth","year":"2019","journal-title":"Clin. Med."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0265","first-page":"15","article-title":"An essential pathology package for low-and middle-income countries","volume":"147","author":"Fleming","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0270","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.sjbs.2023.103920_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-0182-y","article-title":"Novel immunomodulatory drugs and neo-substrates","volume":"8","author":"Gao","year":"2020","journal-title":"Biomarker Res."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0285","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.3390\/ijms23063112","article-title":"Pathogenesis and treatment of myeloma-related bone disease","volume":"23","author":"Gau","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"27\u201328","key":"10.1016\/j.sjbs.2023.103920_b0290","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0295","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.12325","article-title":"D (T) PACE as salvage therapy for aggressive or refractory multiple myeloma","volume":"161","author":"Gerrie","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.sjbs.2023.103920_b0300","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41375-019-0419-7","article-title":"Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma","volume":"33","author":"Goyal","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0305","doi-asserted-by":"crossref","first-page":"e2017052","DOI":"10.4084\/mjhid.2017.052","article-title":"Solitary plasmacytoma","volume":"9","author":"Grammatico","year":"2017","journal-title":"Mediterranean J. Hematol. Infect. Dis."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0310","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4081\/cp.2018.1061","article-title":"Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies","volume":"8","author":"Gr\u00f8nnings\u00e6ter","year":"2018","journal-title":"Clin. Pract."},{"key":"10.1016\/j.sjbs.2023.103920_b0315","doi-asserted-by":"crossref","first-page":"CGM-S16817","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: pathophysiology and management","volume":"7","author":"Hameed","year":"2014","journal-title":"Cancer Growth and Metastasis"},{"issue":"11","key":"10.1016\/j.sjbs.2023.103920_b0320","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/cancers11111738","article-title":"The role and function of microRNA in the pathogenesis of multiple myeloma","volume":"11","author":"Handa","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.sjbs.2023.103920_b0325","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jprot.2015.12.016","article-title":"Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers","volume":"136","author":"Harshman","year":"2016","journal-title":"J. Proteomics"},{"issue":"12","key":"10.1016\/j.sjbs.2023.103920_b0330","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/ijc.33762","article-title":"Epidemiology, genetics and treatment of multiple myeloma and precursor diseases","volume":"149","author":"Hemminki","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.sjbs.2023.103920_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","article-title":"The changing landscape of relapsed and\/or refractory multiple myeloma (MM): fundamentals and controversies","volume":"10","author":"Hern\u00e1ndez-Rivas","year":"2022","journal-title":"Biomarker Res."},{"key":"10.1016\/j.sjbs.2023.103920_b0340","article-title":"Hematology: basic principles and practice","author":"Hoffman","year":"2013","journal-title":"Health Sci."},{"issue":"7","key":"10.1016\/j.sjbs.2023.103920_b0345","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Therapeutic Adv. Hematol."},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0350","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-2-41","article-title":"Skeletal Plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database","volume":"2","author":"Jawad","year":"2009","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.sjbs.2023.103920_b0360","article-title":"Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"4683","author":"Jayaweera","year":"2021","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.sjbs.2023.103920_b0365","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/13543784.2020.1814253","article-title":"CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers","volume":"29","author":"Jiao","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"8","key":"10.1016\/j.sjbs.2023.103920_b0370","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.sjbs.2023.103920_b0375","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1373\/clinchem.2011.171314","article-title":"Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies","volume":"57","author":"Katzmann","year":"2011","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0380","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.sjbs.2023.103920_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1100\/2012\/895765","article-title":"A review for solitary plasmacytoma of bone and extramedullary plasmacytoma","volume":"2012","author":"Kilciksiz","year":"2012","journal-title":"Scientific World J."},{"key":"10.1016\/j.sjbs.2023.103920_b0390","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0395","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/erm.11.44","article-title":"Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management","volume":"11","author":"Kristinsson","year":"2011","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0400","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"issue":"7","key":"10.1016\/j.sjbs.2023.103920_b0405","first-page":"1047","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"12","key":"10.1016\/j.sjbs.2023.103920_b0415","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0420","article-title":"Multiple myeloma and renal failure: Mechanisms, diagnosis, and management","volume":"14","author":"Kundu","year":"2022","journal-title":"Cureus"},{"issue":"25","key":"10.1016\/j.sjbs.2023.103920_b0425","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0430","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0435","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0440","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol."},{"issue":"36","key":"10.1016\/j.sjbs.2023.103920_b0445","doi-asserted-by":"crossref","first-page":"60656","DOI":"10.18632\/oncotarget.19269","article-title":"Emerging drugs and combinations to treat multiple myeloma","volume":"8","author":"Larocca","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0450","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0455","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/curroncol28010063","article-title":"Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects","volume":"28","author":"Lassiter","year":"2021","journal-title":"Curr. Oncol."},{"issue":"7779","key":"10.1016\/j.sjbs.2023.103920_b0460","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","article-title":"The landscape of somatic mutation in normal colorectal epithelial cells","volume":"574","author":"Lee-Six","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0465","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.hoc.2007.08.009","article-title":"Pathophysiology of multiple myeloma bone disease","volume":"21","author":"Lentzsch","year":"2007","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"8","key":"10.1016\/j.sjbs.2023.103920_b0470","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","article-title":"Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growthantitumor activity of mir-21 inhibitors in multiple myeloma","volume":"19","author":"Leone","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.sjbs.2023.103920_b0475","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1002\/ajh.26750","article-title":"Antibody drug conjugates for the treatment of multiple myeloma","volume":"98","author":"Leong","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.sjbs.2023.103920_b0480","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.yexcr.2009.07.001","article-title":"DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1","volume":"315","author":"Lerner","year":"2009","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0485","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.mpdhp.2009.01.009","article-title":"Plasma cell neoplasms","volume":"15","author":"Lin","year":"2009","journal-title":"Diagn. Histopathol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0490","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jim-2019-001010","article-title":"Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma","volume":"68","author":"Liu","year":"2020","journal-title":"J. Invest. Med."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0495","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4065\/mcp.2009.0547","article-title":"Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma","volume":"85","author":"Madan","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.sjbs.2023.103920_b0500","series-title":"Neoplastic Diseases of the Blood","first-page":"531","article-title":"Smoldering multiple myeloma","author":"Mateos","year":"2018"},{"issue":"8","key":"10.1016\/j.sjbs.2023.103920_b0505","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00277-020-04023-4","article-title":"The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma","volume":"99","author":"Merz","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.sjbs.2023.103920_b0510","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","volume":"5","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0515","first-page":"373","article-title":"Multiple myeloma: diagnosis and treatment","volume":"95","author":"Michels","year":"2017","journal-title":"Am. Fam. Physician"},{"issue":"7","key":"10.1016\/j.sjbs.2023.103920_b0520","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/cancers13071527","article-title":"Aminopeptidase expression in multiple myeloma associates with disease progression and sensitivity to melflufen","volume":"13","author":"Miettinen","year":"2021","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.sjbs.2023.103920_b0525","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0530","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0535","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3324\/haematol.2013.096149","article-title":"Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers","volume":"99","author":"Mohty","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0540","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.hemonc.2019.07.001","article-title":"Synchronous multiple myeloma and Gaucher disease","volume":"13","author":"Monge","year":"2020","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.sjbs.2023.103920_b0545","first-page":"1","article-title":"Pathogenesis of Renal Failure in Multiple Myeloma: Any Role of Contrast Media?","volume":"2014","author":"Mussap","year":"2014","journal-title":"Biomed Res. Int."},{"issue":"7","key":"10.1016\/j.sjbs.2023.103920_b0550","first-page":"853","article-title":"Multiple myeloma: diagnosis and treatment","volume":"78","author":"Nau","year":"2008","journal-title":"Am. Fam. Physician"},{"issue":"22","key":"10.1016\/j.sjbs.2023.103920_b0555","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1182\/blood.V128.22.5676.5676","article-title":"High-dose cyclophosphamide in highly refractory multiple myeloma patients as a bridge to further novel therapies","volume":"128","author":"Nikonova","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0560","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0565","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jjco\/hyy108","article-title":"Proteasome inhibitors for multiple myeloma","volume":"48","author":"Okazuka","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0570","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med. Sci."},{"issue":"13","key":"10.1016\/j.sjbs.2023.103920_b0575","first-page":"2068","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"5","key":"10.1016\/j.sjbs.2023.103920_b0580","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.3390\/ijms22052375","article-title":"Multiple myeloma bone disease: implication of MicroRNAs in its molecular background","volume":"22","author":"Papanota","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0585","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10719-017-9773-8","article-title":"Heparan sulfate proteoglycans as key regulators of the mesenchymal niche of hematopoietic stem cells","volume":"34","author":"Papy-Garcia","year":"2017","journal-title":"Glycoconj. J."},{"issue":"35","key":"10.1016\/j.sjbs.2023.103920_b0590","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0595","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies\u2014Current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0600","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.seminhematol.2012.04.011","article-title":"Proteasome inhibitors and bone disease","volume":"49","author":"Qiang","year":"2012","journal-title":"Semin. Hematol."},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0605","first-page":"332","article-title":"Expression level of microRNA-92a and its clinical significance in multiple myeloma patients","volume":"34","author":"Qu","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi= Zhonghua Xueyexue Zazhi"},{"issue":"10","key":"10.1016\/j.sjbs.2023.103920_b0610","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.sjbs.2023.103920_b0615","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.sjbs.2023.103920_b0620","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0625","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0630","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2012.128","article-title":"Redefining myeloma","volume":"9","author":"Rajkumar","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.sjbs.2023.103920_b0635","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3390\/cancers12082113","article-title":"Multiple myeloma associated bone disease","volume":"12","author":"Rasch","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0640","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2015.160","article-title":"Navigating the bone marrow niche: translational insights and cancer-driven dysfunction","volume":"12","author":"Reagan","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0645","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"325","key":"10.1016\/j.sjbs.2023.103920_b0650","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.morpho.2015.02.001","article-title":"Plasma cell morphology in multiple myeloma and related disorders","volume":"99","author":"Ribourtout","year":"2015","journal-title":"Morphologie"},{"issue":"10","key":"10.1016\/j.sjbs.2023.103920_b0655","first-page":"3557","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.sjbs.2023.103920_b0660","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8004","article-title":"A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM)","author":"Richardson","year":"2019","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0665","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.sjbs.2023.103920_b0670","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.sjbs.2023.103920_b0675","first-page":"6669","article-title":"MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"s1","key":"10.1016\/j.sjbs.2023.103920_b0680","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.4081\/hr.2020.8951","article-title":"How we manage smoldering multiple myeloma","volume":"12","author":"Romano","year":"2020","journal-title":"Hematol. Rep."},{"issue":"5","key":"10.1016\/j.sjbs.2023.103920_b0685","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3109\/10428194.2012.733879","article-title":"Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents","volume":"54","author":"Ronchetti","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.sjbs.2023.103920_b0690","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/EDBK_175171","article-title":"Myeloma in elderly patients: when less is more and more is more","volume":"37","author":"Rosko","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0695","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework","volume":"8","author":"Roy","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"12","key":"10.1016\/j.sjbs.2023.103920_b0700","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/qjmed\/hcy165","article-title":"Multiple myeloma and pepperpot skull","volume":"111","author":"Sandal","year":"2018","journal-title":"QJM: An Int. J. Med."},{"key":"10.1016\/j.sjbs.2023.103920_b0705","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00319","article-title":"Serum free light chains in common variable immunodeficiency disorders: role in differential diagnosis and association with clinical phenotype","volume":"11","author":"Scarpa","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0710","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Sch\u00fcrch","year":"2020","journal-title":"Virchows Arch."},{"issue":"11","key":"10.1016\/j.sjbs.2023.103920_b0715","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.21845","article-title":"IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom\u2019s macroglobulinemia","volume":"85","author":"Schuster","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0720","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.26269","article-title":"Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials","volume":"96","author":"Sidiqi","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0725","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.sjbs.2023.103920_b0730","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.3390\/curroncol29070355","article-title":"Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies","volume":"29","author":"Stalker","year":"2022","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.sjbs.2023.103920_b0735","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clml.2019.05.001","article-title":"Retrospective review of the use of high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone for the treatment of multiple myeloma and plasma cell leukemia","volume":"19","author":"Tabchi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.sjbs.2023.103920_b0740","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4329\/wjr.v13.i7.223","article-title":"Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging?","volume":"13","author":"Tagliafico","year":"2021","journal-title":"World J. Radiol."},{"issue":"12","key":"10.1016\/j.sjbs.2023.103920_b0745","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1016\/S1470-2045(13)70404-2","article-title":"Management of multiple myeloma in Asia: resource-stratified guidelines","volume":"14","author":"Tan","year":"2013","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0750","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-019-03858-w","article-title":"Treatment evolution and improved survival in multiple myeloma in Taiwan","volume":"99","author":"Tang","year":"2020","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0755","first-page":"1098","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"18","key":"10.1016\/j.sjbs.2023.103920_b0760","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma\u2013related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0765","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0770","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0775","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.sjbs.2023.103920_b0780","doi-asserted-by":"crossref","unstructured":"Usmani, S.Z., Berdeja, J.G., Madduri, D., Jakubowiak, A.J., Agha, M.E., Cohen, A.D., Hari, P., Yeh, T.-M., Olyslager, Y., Banerjee, A., 2021. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1. Wolters Kluwer Health.","DOI":"10.1016\/j.htct.2021.10.460"},{"issue":"7","key":"10.1016\/j.sjbs.2023.103920_b0785","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.22.02114","article-title":"How we manage newly diagnosed multiple myeloma with circulating tumor cells","volume":"41","author":"van de Donk","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.sjbs.2023.103920_b0790","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"Van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.sjbs.2023.103920_b0795","first-page":"328","article-title":"The future of autologous stem cell transplantation in myeloma","volume":"124","author":"van Rhee","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"11","key":"10.1016\/j.sjbs.2023.103920_b0800","first-page":"2985","article-title":"Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma","volume":"118","author":"Wadhera","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"10","key":"10.1016\/j.sjbs.2023.103920_b0805","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.sjbs.2023.103920_b0810","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0820","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.sjbs.2023.103920_b0825","first-page":"5418","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0830","doi-asserted-by":"crossref","DOI":"10.7812\/TPP\/19.104","article-title":"A tale of two immunodeficiencies: A case of multiple myeloma associated with profound immune defect mimicking common variable immunodeficiency syndrome","volume":"24","author":"Yavorkovsky","year":"2020","journal-title":"Perm. J."},{"issue":"6","key":"10.1016\/j.sjbs.2023.103920_b0835","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.18632\/oncotarget.13314","article-title":"Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.sjbs.2023.103920_b0840","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.sjbs.2023.103920_b0845","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/0008-5472.CAN-15-0457","article-title":"Targeting the miR-221\u2013222\/PUMA\/BAK\/BAX Pathway Abrogates Dexamethasone Resistance in Multiple MyelomaThe Role of miR-221\/222 in Multiple Myeloma Dexamethasone Resistance","volume":"75","author":"Zhao","year":"2015","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.sjbs.2023.103920_b0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Saudi Journal of Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319562X23003650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319562X23003650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:55:01Z","timestamp":1778594101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319562X23003650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":168,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1319562X23003650"],"URL":"https:\/\/doi.org\/10.1016\/j.sjbs.2023.103920","relation":{},"ISSN":["1319-562X"],"issn-type":[{"value":"1319-562X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of multiple myeloma: A monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities","name":"articletitle","label":"Article Title"},{"value":"Saudi Journal of Biological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sjbs.2023.103920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author. Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}],"article-number":"103920"}}